Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
15 avr. 2024 07h00 HE
|
Gritstone bio
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor...
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
08 avr. 2024 08h00 HE
|
Gritstone bio
EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
08 avr. 2024 07h00 HE
|
Gritstone bio
-- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive...
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
01 avr. 2024 23h00 HE
|
Gritstone bio
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Proposed Public Offering
01 avr. 2024 16h10 HE
|
Gritstone bio
EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
01 avr. 2024 16h01 HE
|
Gritstone bio
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction...
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
05 mars 2024 16h05 HE
|
Gritstone bio
-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC)...
Gritstone bio Announces Workforce Reduction
29 févr. 2024 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
21 févr. 2024 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
12 févr. 2024 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced...